跳到正文
原文
The Lancet Oncology· Martin F Kaiser, Rachel H Phillip, Sarah R Brown, Amy Holroyd, Elsa Ferris, Ruth M de Tute, Sadie Roberts, Laura Clayton, Kristian Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S Houlston, Graham Jackson, Gordon Cook, Roger G Owen, Mark T Drayson, Guy Pratt, Andrew Hall, Matthew W Jenner·· 2026-09-08精选AI 评分72

OPTIMUM研究5年随访:达雷妥尤单抗联合四药强化方案治疗高风险多发性骨髓瘤

[Articles] Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial

AI 导读

OPTIMUM研究5年随访数据显示,对风险分层患者采用达雷妥尤单抗联合环磷酰胺、硼替佐米、来那度胺和地塞米松的诱导及延长巩固治疗,可维持无进展生存期和总生存期获益。研究团队认为,这支持在新诊断的高风险多发性骨髓瘤患者中实施分子诊断和个体化治疗。

推荐理由

OPTIMUM研究5年随访数据在高风险多发性骨髓瘤中展示分层强化治疗的持续获益,为分子分型指导治疗提供依据。

来源:The Lancet Oncology · thelancet.com